Acute Lymphoblastic Leukemia Archives

Phase 3 Trial Evaluates Inotuzumab Ozogamicin Plus Frontline Chemotherapy in B-Cell ALL

By

July 2, 2021

Investigators seek to evaluate how the addition of inotuzumab ozogamicin to frontline chemotherapy affects patients with newly diagnosed B-cell ALL.

Leukemia

Reducing Maintenance Produced ‘Outstanding’ Survival Outcomes in Pediatric Acute Lymphoblastic Leukemia

By

Sucharita Mistry, PhD

July 1, 2021

Survival rates were similar whether maintenance was given every 12 weeks or every 4 weeks.

Leukemia

Transcranial Direct Current Stimulation in Adult Survivors of Pediatric Acute Lymphoblastic Leukemia

By

Cancer Therapy Advisor Staff

June 30, 2021

The primary outcome of the study is to evaluate the efficacy of home-based tDCS combined with remote cognitive training on direct testing of executive function in survivors of ALL.

Median overall survival was 42 months in patients who received sorafenib and 13 months in patients who received chemotherapy alone.

Leukemia

Acute Lymphoblastic Leukemia Patients With Half-Matched Donors See Improved Outcomes

By

Christina Bennett, MS

May 20, 2021

Outcomes have improved during the past decade for patients with acute lymphoblastic leukemia who undergo haploidentical hematopoietic cell transplantation.

Leukemia

Azacitidine Shows Safety in Infants With KMT2A-Mutant Acute Lymphoblastic Leukemia

By

Jonathan Goodman, MPhil

May 10, 2021

Researchers sought to determine whether using azacitidine would be safe for infants with ALL with a KMT2A rearrangement.

Nilotinib in combination with chemotherapy is highly effective in Philadelphia chromosome-, BCR-ALB1

Leukemia

Short-Term 6-TG Exposure During Treatment for Pediatric ALL Associated With Hepatic SOS

By

Colby Stong

April 28, 2021

Investigators analyzed the association between hepatic SOS and short-term application of 6-TG in 3983 pediatric ALL patients.

$ASP2215 is well tolerated in doses of up to 300 mg per day in patients with relapsed or refractory A$

Leukemia

Diet, Exercise Intervention Explored in Children With B-ALL

April 28, 2021

Reduction in fat gain not seen in overall cohort, but stratified analysis showed benefit among those overweight, obese at baseline.

Leukemia

High Cortactin, HS1 Levels Predict Worse Survival in Patients With B Cell Acute Lymphoblastic Leukemia

By

Jonathan Goodman, MPhil

April 19, 2021

Researchers sought to determine whether high cortactin and HS1 expression may be linked with poorer prognosis for patients with B-ALL.

A study showed how long patients with CLL may live after CAR-T therapy failure, providing a benchmark for trials evaluating therapies in the post–CAR-T setting.

Leukemia

Genetic Mutations May Add to Racial Disparity in Child B-ALL

March 12, 2021

Increased incidence of IKZF1 deletion and IGH-CRLF2 translocation seen in Hispanic/Latino children with B-ALL.

Over half of patients receiving azacitidine maintenance achieved protocol completion.

Leukemia

Pyridoxine Plus Pyridostigmine Beneficial for Neurotoxicity in ALL

By

Patricia Chaney

February 26, 2021

A team of investigators prospectively evaluated pediatric patients with ALL to determine the effectiveness of pyridoxine (vitamin B6) plus pyridostigmine therapy for vincristine-induced neurotoxicity.